Rhodiola Rosea for Stress, Fatigue, and Burnout: What the Evidence Shows

Rhodiola rosea — golden root, Arctic root — is sold as the adaptogen for people running on empty: the wired-but-tired, the burned-out, the chronically stressed.

Here’s the honest version. Rhodiola has real randomized-trial signals for stress-related fatigue and mild anxiety. In controlled studies it beats placebo on fatigue and attention, and it’s generally well tolerated over a few weeks. But the evidence base is thin: the trials are small, each one tests a different branded extract, industry involvement is common, and two systematic reviews concluded the studies are contradictory and at high risk of bias. It’s a plausible short-term tool for stress and fatigue — not a proven one.

This is the strongest part of the case, and it rests largely on one study.

A 2009 double-blind RCT (Olsson et al.) in Planta Medica is the most-cited trial. It randomized 60 adults diagnosed with fatigue syndrome to 576 mg/day of the SHR-5 extract or placebo for 28 days. Both groups improved (a real placebo effect), but when compared head-to-head, the SHR-5 group did significantly better on Pines’ burnout scale and on several attention measures — fewer errors and steadier reaction times on a computerized attention test. The extract also blunted the cortisol response to awakening relative to placebo. The authors concluded rhodiola “exerts an anti-fatigue effect that increases mental performance, particularly the ability to concentrate.”

That’s a genuinely positive result. Keep the scale in mind though: 60 people, 28 days, one extract.

Does it reduce anxiety?

The anxiety evidence is weaker and comes from trials with obvious design holes.

A 2015 RCT (Cropley et al.) in Phytotherapy Research randomized 80 mildly anxious participants to 400 mg/day of a rhodiola extract (Vitano) or a control condition for 14 days. The rhodiola group reported significant reductions in anxiety, stress, anger, confusion, and depression, plus improved total mood. But note the catch the authors flag themselves: there was no placebo. The control group got no treatment at all, so expectation effects can’t be ruled out.

Go back further and it thins out more. A 2008 pilot study (Bystritsky et al.) gave 340 mg/day to just 10 people with diagnosed generalized anxiety disorder for 10 weeks. Anxiety scores dropped significantly (p = 0.01) — but with no control group and 10 participants, this is hypothesis-generating, not proof. It’s the same evidence-quality problem you’ll see across the anxiety supplement literature: promising direction, fragile methods.

What about burnout specifically?

The headline burnout study is encouraging and, on paper, the largest — but read the design closely.

A 2017 trial (Kasper & Dienel) in Neuropsychiatric Disease and Treatment gave 400 mg/day of the WS 1375 extract (Rosalin) to 118 outpatients with burnout symptoms for 12 weeks. A wide range of burnout, stress, and mood measures “clearly improved,” some within the first week, and side effects were rare.

Here’s the information-gain the supplement marketing skips: this was an open-label, single-arm trial with no control group. Everyone knew they were taking rhodiola, and there was no placebo to compare against. The authors are explicit that it was designed only “to provide the exploratory data required for planning future randomized trials.” In other words, it’s a signal to justify a real trial — not evidence the extract works. In a 12-week study of people expecting to feel better, some improvement is exactly what you’d predict regardless of the pill.

Why is the evidence considered weak overall?

Because the people who’ve pooled it say so, plainly.

A 2011 systematic review (Hung, Perry & Ernst) in Phytomedicine found 11 RCTs, all placebo-controlled, with signals for physical performance, mental performance, and some mental-health conditions. Their core caveat: there was “a lack of independent replications” — most findings came from single studies that no one else had reproduced.

A 2012 systematic review (Ishaque et al.) focused on fatigue was blunter. Of the trials included, only 2 of 6 physical-fatigue studies and 3 of 5 mental-fatigue studies were positive — and critically, “all of the included studies exhibit either a high risk of bias or have reporting flaws” that prevented the reviewers from judging their true validity. Their verdict: the research is contradictory, and a rigorous, well-reported RCT is still needed.

There’s a second, quieter problem. Every trial above uses a different proprietary extract — SHR-5, Vitano, WS 1375/Rosalin — often with the manufacturer involved. These aren’t interchangeable. A result for SHR-5 doesn’t automatically transfer to whatever capsule is on the shelf, which may not be standardized to the same rosavin and salidroside content at all.

So should you take it?

If you want to try rhodiola for short-term stress or fatigue, the risk profile is reasonable: trials up to 12 weeks report mostly mild side effects (occasional dizziness or dry mouth), and no serious harms attributable to the extract. That’s a low bar to clear for a short trial.

Just calibrate your expectations to the evidence. The realistic case is a modest, short-term nudge on fatigue and concentration — not a cure for burnout. Burnout that’s rooted in workload, sleep debt, and recovery won’t be fixed by a capsule; the drivers of burnout recovery sit upstream of any supplement. If you do experiment, buy an extract that lists standardization (typically 3% rosavins, 1% salidroside), take it earlier in the day, give it two to four weeks, and judge it on how you actually function — the same skeptical approach worth applying to any supplement marketed for stress.

For the bigger picture on non-drug tools for a dysregulated nervous system, see the pillar guide on anxiety regulation and sleep restoration.